Effects of ospemifene on overactive bladder in postmenopausal women with vulvovaginal atrophy.
E RussoG MisasiMaria Magdalena Montt-GuevaraTommaso SimonciniTommaso SimonciniPublished in: Climacteric : the journal of the International Menopause Society (2023)
Our study suggest that treatment with ospemifene in PMW suffering from OAB is associated with a reduction of OAB symptoms due to a decreased bladder sensitivity and with an improvement in quality of life.